Gregory Adams

Company: Elucida Oncology Inc.

Job title: Chief Scientific Officer

Seminars:

Nonclinical & Clinical Toxicity Assessment of ELU001, a C’Dot Drug Conjugate (CDC) Targeting Folate Receptor Alpha 1:30 pm

Deep diving into a case study of a C’Dot Drug Conjugate Selecting appropriate models to determine safety profiles Looking at what has been seen in the trial relating to learnings from tox studiesRead more

day: Day One

Advancing your ADC Candidates Into the Clinic Faster with Improved Preclinical Models for Identifying Toxicity 9:00 am

A major challenge in ADC drug development is knowing what animal models will cross react with your ADC candidate, and how well these models will pick up toxicity to translate into your clinic which can cause costly and deadly delays to clinical programs. Take part in this deep dive session to learn all about in…Read more

day: Pre-Conference Day